CrCl ϭ creatinine clearance; NSTE-ACS ϭ non-ST-segment elevation acute coronary syndromes; PCI ϭ percutaneous coronary intervention.
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In this paper we review the major developments in the field of non-ST-segment elevation acute coronary syndromes (NSTE-ACS) that were published between June 2010 and May 2011.
Background
Heidenreich et al. (1) , in a document prepared for the American Heart Association (AHA), forecasts that cardiovascular disease (CVD) prevalence and costs are projected to continue to increase substantially, with more than 40% of individuals having some form of CVD by 2030. Acute coronary syndrome (ACS) represents the most common initial presentation of CVD, and although rates of STsegment elevation myocardial infarction (STEMI) are falling, the proportion of all acute infarcts comprised by non-ST-segment elevation myocardial infarction (NSTEMI) increased from 53% to 77% in the past decade ( Fig. 1) (2) . Treatment gaps persist despite publication of widely disseminated practice guidelines, which are continually updated (3, 4) .
Guideline Focused Update
The American College of Cardiology Foundation and the AHA released a focused update on the management of patients with unstable angina and NSTEMI (3) in 2011 that incorporated new information since the previous version in 2007. The key changes are summarized in Table 1 . The European Society of Cardiology updated its guideline in 2011 as well (4) .
Pathophysiology
Considerable effort continues on understanding the natural history of the progression of atherosclerosis, the relationship between plaque morphology and type of ACS event, and the prognosis in patients with coronary spasm. Characteristics of coronary arterial plaques that favor development of an NSTE-ACS (compared with STEMI) studied by using optimal coherence tomography (OCT) include the absence of previous plaque rupture (53% vs. 30%; p ϭ 0.033), absence of thin-cap fibroatheromas (51% vs. 22%; p ϭ 0.008), and absence of red thrombus (73% vs. 22%; p Ͻ 0.001) (6) . Furthermore, among patients with unstable angina, the severity of symptoms varied with plaque structure as identified by using OCT (7) . Patients with the most severe presentation (Braunwald class III [angina at rest within 48 h]) were more likely to have thin-cap fibroatheromas with spotty classifications (p Ͻ 0.001 for both). Patients with Braunwald class I symptoms had the highest frequency of ulcers without fibrous cap disruption (p ϭ 0.003). Table 2 provides a listing of the relevant study names and acronyms discussed here. In the PROSPECT trial (8) , 697 patients with ACS underwent coronary angiography and intravascular ultrasound imaging after percutaneous coronary intervention (PCI) to characterize culprit and nonculprit lesions throughout the coronary tree. Major cardiovascular events over a median follow-up of 3.4 years occurred equally at the site of lesions that had previously been responsible for an ACS and those that had not (culprit vs. nonculprit lesions). The nonculprit lesions were most frequently nonobstructive (32 Ϯ 21% diameter stenosis by angiography) and had a large plaque burden and/or luminal area Ͻ4 mm 2 , characteristic of a high risk of future rupture ( Fig. 2) (8) . Therefore, to prevent future cardiovascular events, more intensive therapies directed at nonculprit lesions that are typically nonobstructive, yet vulnerable to rupture, are required.
However, the optimal imaging technique for identifying vulnerable plaques remains to be identified. A comprehensive review of the histological validation of a variety of invasive (e.g., intravascular ultrasound, palpography, OCT, near-infrared spectroscopy, intravascular magnetic resonance imaging [MRI] , angioscopy, thermoscopy, shear stress imaging) and noninvasive (e.g., multidetector com-puted tomography, MRI, nuclear, ultrasound) imaging techniques available to assess vulnerable plaques concluded that the diagnostic and predictive accuracy of each of these methods needs to be evaluated in large prospective studies before they could be incorporated into clinical practice (9) . Inevitably, these techniques will have to be compared in cost-effectiveness analyses.
Interestingly, the 3-year follow-up of the CASPAR Study (10) of patients with coronary artery spasm as the cause of ACS (more frequently associated with Braunwald class II unstable angina, which had developed between 48 hours and 1 month earlier) demonstrated an excellent prognosis, with no cardiac death or nonfatal myocardial infarction (MI), compared with 11% in those with a detectable culprit lesion. However, 50% of patients without a culprit lesion continued to experience angina during the 3-year follow-up phase, which presents a challenge to the quality of life in these patients with coronary spasm.
Risk Stratification
The 6 goals of cardiovascular risk assessment are to: 1) achieve effective triage; 2) direct the need for additional testing; 3) identify patients who need referral to a subspecialist; 4) guide therapeutic decision making; 5) optimize allocation of clinical resources; and 6) inform patients and families of the prognosis (11) . Research reported during the past year added new information that helps clinicians attain these goals.
Numerous triggers of plaque rupture and MI have been identified, but new data incorporating both the strength of the relationship and the prevalence of exposure to calculate a population-attributable risk fraction have become available (12) . Factors with the greatest population-attributable risk for triggering an MI were traffic exposure, physical exertion, alcohol, coffee, and air pollution. Among these triggers, a large body of new information on particulate matter (PM) air pollution led to a recent update to the AHA 2004 Scientific Statement on this subject (13) . The key findings were that exposure to fine PM (i.e., Ͻ2.5 M in diameter) in the short-term (few hours to weeks) increases the risk for CVD-related mortality, hospitalizations, and ischemic heart disease, whereas longer-term exposure reduces life expectancy. Thus, the AHA deemed PM Ͻ2.5 M to be a modifiable factor that contributes to cardiovascular morbidity and mortality, including both fatal and nonfatal ischemic heart disease. Gersh et al. (14) reviewed how hostile factors in the environment (e.g., air pollutants) interact with predisposing factors of cardiovascular events and genetic/ phenotypic vulnerability, thus leading to the current epidemic of cardiovascular disease in low-and middle-income countries (Fig. 3) .
New data on risk stratification from a multinational observational study in the Asia-Pacific region identified a very-low-risk profile of patients who present to the emergency department with chest pain. All patients had chest discomfort lasting at least 5 min consistent with NSTE-ACS and plans for serial biomarker assessment. Use of the Thrombolysis In Myocardial Infarction (TIMI) risk score for unstable angina (15) and a point-of-care biomarker panel of troponin, creatine kinase-myocardial band, and myoglobin, in addition to a standard 12-lead electrocardiogram as part of a 2-h accelerated diagnostic protocol, classified 9.8% of patients as low risk (0.9% rate of major adverse cardiac events through 30 days) with a sensitivity of Major Modifications to the 2011 NSTE-ACS Practice Guideline The rates of cardiac death, cardiac arrest, myocardial infarction, or hospitalization for unstable angina or progressive angina through a median of 3.4 years after percutaneous coronary intervention are shown for nonculprit lesions characterized using intravascular ultrasound as thin-cap fibroatheromas (TCFA) (n ϭ 595) or not TCFA (n ϭ 2,114), with or without a minimal luminal area (MLA) Յ4 mm 2 and/or plaque burden (PB) Ն70%. The inset shows a TCFA imaged by using radiofrequency ultrasonography. CI ϭ confidence interval; PROSPECT ϭ Providing Regional Observations to Study Predictors of Events in the Coronary Tree. Reprinted, with permission, from Stone et al. (8) . ventricular tachycardia as short as 4 to 7 beats on continuous electrocardiographic recording during the first 7 days after an NSTE-ACS, had an adjusted hazard ratio (HR) for sudden cardiac death of 2.3 (p Ͻ 0.001) (17) . Whether such patients may benefit from electrophysiological evaluation requires further prospective assessment. Other specific subgroups of patients with ACS at particularly high risk and who may require referral to a subspecialist include patients with depressive symptoms (18) and those infected with human immunodeficiency virus (19) .
Trial Acronyms

Biomarkers
Pletcher and Pignone (20) published a comprehensive review of the clinical utility of biomarkers, focusing on methods to estimate their clinical impact on the patient and clinical decision making. Judged in this context, the most important development in the past year for ACS was the further implementation of sensitive troponin assays, which increased the frequency of diagnosis of MI (21) and identified additional patients at high risk of reinfarction and death (21, 22) . In a single-center, prospective evaluation, lowering the diagnostic threshold of a sensitive troponin I assay from 0.20 to 0.05 ng/ml reclassified patients with troponin values of 0.05 to 0.19 ng/ml as NSTEMI instead of unstable angina (21) . This reclassification resulted in more aggressive treatment of patients with this lower-level "positive" troponin, a reduction in morbidity and mortality (21) , and explains in part the increasing incidence of NSTEMI over the past decade ( Fig. 1 ).
Despite the wider adoption of more sensitive troponin assays, 2 large multicenter registries identified 2 groups of patients with NSTEMI who are still less likely to receive guideline-recommended therapy although their biomarker pattern satisfied current criteria for MI. Use of initial antiplatelet and anti-ischemic therapy, statins, and longterm clopidogrel were underused in patients with an elevated troponin but normal creatine kinase-myocardial band (i.e., troponin ϩ, myocardial band Ϫ) (23) as well as patients in whom the first troponin values were negative but who were subsequently ruled-in for NSTEMI (24) . These findings identify opportunities to improve clinical decision making with serial measurement and proper interpretation of more sensitive troponin assays.
One disadvantage of the use of more sensitive troponin assays is the higher rate of false positives, which can lead to the use of acute pharmacological therapies and coronary angiography in patients who do not have NSTE-ACS (25) . Indeed, they may not even have ischemic heart disease (26) . Careful consideration of the clinical context of the elevated troponin and use of serial and/or multimarker strategies (as discussed in the following text) are methods that can reduce the misinterpretation of such findings.
Elevated levels of midregional pro-adrenomedullin (sAM), a peptide fragment of the vasodilatory peptide adrenomedullin known to be elevated in heart failure and post-ACS, was prognostic for death or heart failure in patients with NSTEMI (27) . Admission levels of sAM were independently associated with mortality at 30 days, even after adjustment for the GRACE score and N-terminal pro-B-type natriuretic peptide (NT-proBNP). However, whether heart failure biomarkers are useful for guiding treatment decisions and improving outcomes-the most important test of a biomarker (28)-remain a challenge.
When such a strategy was tested in the AVANT GARDE-TIMI 43 trial of patients post-ACS with left ventricular ejection fraction (LVEF) Ͼ0.40, no overt heart failure, and elevated B-type natriuretic peptide (BNP), the addition of aliskiren, valsartan, or their combination did not reduce levels of natriuretic peptides over an 8-week period compared with placebo (29) .
Newer research on neopterin and heart-type fatty acidbinding protein have built on previous results described in our 2009 publication (30) . In the PROVE IT-TIMI 22 trial in post-ACS patients, neopterin, a marker of monocyte activation, was found to be an independent predictor of subsequent hospitalization for heart failure, and it improved risk prediction when it was added to models including traditional risk factors, high-sensitivity C-reactive protein (hsCRP), and BNP in patients post-ACS enrolled in the PROVE IT-TIMI 22 trial (31). Heart-type fatty acidbinding protein was shown to be an independent predictor of death or MI. Among patients with suspected ACS and normal troponin, it was used to identify patients at high risk for adverse events (32) .
Progress has also been made in the use of multimarker strategies in the assessment of risk in patients with NSTE-ACS. In an analysis of 4,352 patients with NSTE-ACS enrolled in the MERLIN-TIMI 36 trial, both troponin I and NT-proBNP substantially improved risk prediction when added to clinical risk variables, whereas the inflammatory biomarkers myeloperoxidase and hsCRP did not provide additional prognostic information (33) . Of 9 in- flammatory, ischemic, or neurohormonal biomarkers measured within 48 hours after symptom onset in 440 patients with NSTE-ACS enrolled in the ARCHIPELAGO trial, levels of interleukin-6 (which stimulates the hepatic synthesis of C-reactive protein) was independently correlated with subsequent ischemic endpoints (34) . Meanwhile, the combination of BNP, aldosterone, and matrix metalloproteinase-9, when added to the GRACE clinical risk score, predicted heart failure. In another study of 10 biomarkers measured in 448 subjects with suspected NSTE-ACS presenting to 5 US emergency departments, those with a trio of markers (troponin I, BNP, and placental growth factor) with normal values identified a very-low-risk cohort with event-free rates at 30 and 365 days of 97% and 96%, respectively (35) . In summary, we believe that the most likely advances in the past year from the biomarker field which will have a lasting impact on the clinical practice of patients with NSTE-ACS are the introduction of ultrasensitive troponin assays and the concept of multimarker strategies to identify very-low-risk cohorts.
Imaging
Cardiac MRI using a rapid-scan protocol can evaluate ventricular wall edema, perfusion, wall motion, and identify myocardium at risk in patients with NSTE-ACS (36) . Such findings could then be helpful in guiding PCI in patients with multiple lesions or those with equivocal findings at coronary arteriography (Fig. 4) .
Several studies published in the past year have demonstrated the prognostic utility of echocardiography in the evaluation of patients with NSTE-ACS. In such patients with preserved LVEF, echocardiographic findings of mechanical dyssynchrony were associated with an increased risk of heart failure (37). Another study from the GRACE registry reported that women with a supernormal LVEF (Ͼ65%) had a 2.5-fold increase in the odds of both in-hospital death and cardiac arrest/ventricular fibrillation (38) , possibly related to diastolic dysfunction and/or the presence of hypertrophic heart disease. Several echocardiographic parameters, including abnormal segmental myocardial perfusion using contrast echocardiography (39), abnormal wall motion (39, 40) , tricuspid annular plane systolic excursion (40) , and ultrasound lung comets (extravascular lung fluid observed on ultrasound thoracic scanning) (40) , added prognostic information to standard risk scores such as the TIMI unstable angina risk score (15) and the GRACE risk score in ACS (41) .
Treatment
Antiplatelet agents. Platelets play a central role in the pathogenesis of NSTE-ACS and hence antiplatelet agents play an equally important role in its management. Clopi- dogrel, the most widely used P2Y 12 platelet receptorblocking agent, exhibits substantial interpatient variability in its antiplatelet effect. Studies of various strategies to ensure a more uniform higher antiplatelet effect-namely, the use of higher-dose regimens, dose modification in patients with a measured or predicted low antiplatelet effect, and use of more potent antiplatelet agents-dominated the last year in antiplatelet research in NSTE-ACS. In the CURRENT-OASIS 7 trial (42), a loading dose of 600 mg of clopidogrel followed by 150 mg daily for 6 days and 75 mg daily thereafter did not reduce the primary composite endpoint (cardiovascular death, MI, and stroke through 30 days) compared with standard-dose clopidogrel (300-mg loading dose, 75-mg daily maintenance dose) in the entire study population of 25 (43) , the ability to predict who will need PCI is difficult in patients with NSTE-ACS, and this benefit should be weighed against the statistically significant 41% relative increase in major bleeding (43) . Even when tested among patients with high platelet reactivity after drug-eluting coronary stenting, double-dose clopidogrel (compared with the standard dose) did not reduce the primary composite of cardiovascular death, MI, or stent thrombosis among 2,214 patients enrolled in the GRAVITAS trial (44) . Similarly, there were no differences in cardiovascular ischemic events between higher-dose (300 to 325 mg daily) or lower-dose (75 to 100 mg daily) aspirin in the overall cohort or among those with NSTE-ACS in the CURRENT-OASIS 7 trial.
Two large meta-analyses, one involving 9 studies in 9,685 patients undergoing PCI (55% of whom had ACS [ Fig. 5 ]) (45) and the second involving 10 studies in 11,959 patients with an indication for clopidogrel (46) , were reported. Both concluded that reduced-function CYP2C19 alleles expose patients treated with clopidogrel to an increased risk of cardiovascular events, stent thrombosis, and cardiovascular death. A pharmacodynamic hyporesponse to clopidogrel can be overcome in 88% of patients with the 2C19*2 loss of function polymorphism by using repeated loading doses of clopidogrel 600 mg. However, as many as 3 additional doses of 600 mg over 24 h may be needed (hence limiting the practical application), and the clinical benefit of such large doses has not been evaluated (47) . An analysis of patients with NSTE-ACS from the CURE trial did not show an interaction between CYP2C19 genotype and either efficacy or bleeding with clopidogrel (compared with placebo) (48) . However, the infrequent use (21%) of PCI in CURE may explain, in part, the lack of an effect of the CYP450 genotype in these studies.
Two studies reported conflicting results regarding the impact of paraoxonase-1 (PON1), an enzyme involved in clopidogrel bioactivation, on platelet aggregation and stent thrombosis in patients receiving clopidogrel after intracoronary stenting (49,50). Bouman et al. (49) found, using in vitro testing, that conversion of 2-oxo-clopidogrel to the thiol compound was the rate-limiting step of clopidogrel bioactivation, with PON1 representing the key enzyme. In a case-control analysis of 41 patients with nonfatal stent thrombosis compared with 71 randomly selected subjects without stent thrombosis, individuals with the PON1 QQ192 genotype were more frequently represented in the stent thrombosis group than in the control group (odds ratio [OR]: 3.6 [95% CI: 1.6 to 7.9]; p ϭ 0.003) . However, in [55] ), ticagrelor was as effective at reducing the primary composite of cardiovascular death, MI, and stroke as it was in the trial overall (HR: 0.84). Thus, there seems to be a benefit that exists outside of the peri-PCI period as well. Ongoing studies are evaluating the potential benefit of prasugrel in NSTE-ACS outside of the peri-PCI window, including before PCI, in the ACCOAST trial (56) , and in patients who are medically managed without planned PCI, in the TRILOGY ACS trial (57) .
Blockade of the protease-activated receptor 1 on platelets (site of thrombin binding) represents another promising target to inhibit platelet function (also reviewed in 2010 [55] ). Two Phase II trials (LANCELOT-ACS [58] and a sister study conducted in Japan [59] ) demonstrated the safety and feasibility of blocking this receptor with atopaxar, with a reduction in ischemia observed on Holter monitoring (58) . However, significant dose-dependent increases in liver function abnormalities and prolongation of the QT intervals were observed in the Japanese trial (59) . A large phase III trial with vorapaxar in patients with ACS was stopped early due to an increased risk of bleeding in patients with prior stroke at the request of the Data Safety Monitoring Board (60) , and results are expected in late 2011.
Although it has been established that proton pump inhibitors (PPIs) reduce the measurable antiplatelet effect of clopidogrel in the laboratory (61) , the clinical relevance of this interaction remains controversial (5) . A meta-analysis of 13 trials involving 48,674 subjects treated with clopidogrel for a variety of indications concluded that PPIs increased the odds of major cardiovascular events and mortality by 41% and 18%, respectively (both p Ͻ 0.001) (46) . However, a French registry of 3,670 patients with acute MI did not find any differences in cardiovascular events or mortality for patients administered clopidogrel with a PPI versus without a PPI within 48 h after admission (62) . In the COGENT trial (63) , the only large placebo-controlled randomized trial evaluating the clinical risks and benefits of PPI when added to clopidogrel and aspirin in patients with ACS or PCI, there was no increase in cardiovascular events with omeprazole (HR: 0.99 [95% CI: 0.68 to 1.44]), whereas gastrointestinal events were substantially reduced (HR: 0.34 [95% CI: 0.18 to 0.63]).
Bleeding
Hemorrhagic complications in patients with NSTE-ACS not only add to the discomfort and morbidity experienced by patients but are fatal in rare instances and also lower the likelihood of oral antiplatelet therapy prescription at discharge (64); the latter increases the risk of subsequent ischemic events. In an analysis of Canadian patients with NSTE-ACS enrolled in 4 registries, rates of major bleeding remain relatively low (1.7%) and do not seem to have increased over the past decade despite the increased use of dual antiplatelet therapy and invasive procedures (65) . Meanwhile, a large U.S. MI registry of patients more frequently managed with an invasive approach reported rates of major bleeding that were 5-fold higher (66) .
Although bleeding clearly adds to patient morbidity, analyses of patients with STEMI in the EXTRACT-TIMI 25 trial (67) and, more recently, in patients with ACS undergoing PCI in the TRITON-TIMI 38 trial (68) have drawn attention to the complexities inherent in analyses that evaluate impact of bleeding on subsequent clinical outcomes such as mortality. Two important challenges identified in these analyses are the presence of a large amount of confounding due to differences in baseline characteristics when comparing outcomes in patients who bleed versus those who do not. Serious bleeding has been found to be associated with an increase in subsequent adverse events, but it is the patients at high risk of clinical events who have a greater likelihood of bleeding (Fig. 6) .
Approaches to reduce bleeding (and hence improve short-and long-term outcomes) have included risk assessment with subsequent adjustment in the medical and/or invasive strategy, use of new potentially safer agents, reduction in the intensity of the antithrombotic regimen, and implementation of strategies to mitigate bleeding. Several studies explored new or modified bleeding scores in an attempt to better estimate the risk of bleeding in patients with NSTE-ACS and help guide therapy. An integer risk score based on 6 baseline measures plus anticoagulation regimen performed well in the identification of patients at increased risk for non-CABG-related bleeding and mortality at 1 year in 2 trials with bivalirudin in patients with ACS (Table 3) (69) . A model using 12 factors to predict inhospital major bleeding from the ACTION Registry-GWTG database was derived and validated in a total of more than 80,000 patients with MI, demonstrating good 2348 Giugliano
discrimination (c statistics of 0.73 and 0.71 in derivation and validation cohorts, respectively) (70) . How these newer models compare with the more established CRUSADE bleeding risk score (71) remains to be seen. Another strategy to reduce bleeding is to tailor the antithrombotic regimen for patients based on their predicted risk of bleeding. An analysis from the ACTION registry (72) showed that lower rates of bleeding could be achieved in patients with ACS undergoing PCI with a less intensive antithrombotic regimen (either unfractionated heparin [UFH] or bivalirudin monotherapy). A reduction in bleeding was observed even though the patients who received the less intensive antithrombotic regimen were predicted to be at high risk of bleeding compared with those who received a more intensive antithrombotic regimen (combining an anticoagulant with a glycoprotein IIb/IIIa inhibitor). Whether the reduction in bleeding that can be achieved with a less intensive antithrombotic regimen would be offset by an increase in ischemic complications in these patients will require further prospective evaluation.
One important study that investigated a novel anticoagulant regimen was the FUTURA/OASIS 8 trial in which a strategy of fondaparinux 2.5 mg subcutaneously before PCI followed by a standard UFH regimen of 85 U/kg bolus (reduced to 60 U/kg if a glycoprotein IIb/IIIa antagonist was used), with additional boluses guided by activated coagulation time measurements, was as safe as a low-dose UFH regimen of 50 U/kg (73) . Thus, for patients with Figure 6 Death After Different Types of Bleeding in the TRITON-TIMI 38 Study
Hazard ratios (red) and 95% confidence intervals (blue) for death according to time after different types of bleeding. Each red dot represents the hazard ratio for death at the corresponding day after bleeding event compared with patients at the same time in the trial without a bleeding event. Spontaneous bleeding events were associated with a greater risk of death, although the hazard ratios for both spontaneous and instrumented/traumatic bleeding events declined rapidly in the first few days, and spontaneous bleeding did not differ statistically from 1.0 after ϳ5 and ϳ32 days, respectively. Giugliano and Braunwald November 22, :2342 Year in NSTE-ACS NSTE-ACS who receive fondaparinux, the familiar use of UFH in the catheterization laboratory guided by activated coagulation time is a reasonable antithrombotic strategy to support PCI. Factor IXa represents a new and interesting target for inhibition in patients with PCI and ACS. Phase II data with a reversible parenteral direct factor IXa inhibitor in patients undergoing PCI were shown to be simple, safe, and effective during PCI (74) . We look forward to future studies comparing the clinical outcomes of this approach with current standard anticoagulant agents.
Reducing the dose of current standard antithrombotic agents represents an alternate approach to minimizing bleeding. In the ISAR-REACT 3A study (75) , patients with negative biomarkers treated with UFH and clopidogrel before PCI had less bleeding without compromising ischemic protection when a lower single-bolus dose of heparin (100 U/kg) compared with the standard UFH regimen in Germany of 140 U/kg was used. In these low-risk patients, there seems to be little evidence to support the use of intensive antithrombotic regimens, and lower doses seem to be safer.
Among patients undergoing PCI, other options to reduce bleeding include the use of femoral arterial closure devices, bivalirudin monotherapy (in place of UFH or low molecular-weight-heparin) and use of radial (instead of femoral) arterial access. The use of femoral closure devices in patients treated with bivalirudin without a glycoprotein IIb/IIIa inhibitor was associated with a low rate of bleeding complications (76) . However, an analysis from the ACTION registry showed that this approach paradoxically tended to be used least frequently in patients at highest risk for bleeding (69) . An alternative strategy is to use radial arterial access. In a randomized trial comparing radial and femoral arterial access (77), radial access was associated with fewer vascular complications and a 60% reduction in the odds of a large hematoma; there was no difference in the primary composite of death, MI, stroke, or non-CABG-related bleeding. Thus, interventional cardiologists have options to reduce bleeding, whether they have been trained in radial arterial access or the more traditional femoral arterial access.
Lastly, because patients who require long-term triple oral antithrombotic therapy (e.g., patients with ACS managed with an intracoronary stent and atrial fibrillation requiring dual antiplatelet therapy and oral anticoagulation) are at high risk of bleeding, a European Society of Cardiology Consensus document recommends assessment of hemorrhagic risk and tailored therapy to reduce bleeding (78) . These guidelines suggest shortened courses of dual antiplatelet therapy (6 months for drug-eluting stents) combined with warfarin targeting an international normalized ratio of 2.0 to 2.5 in patients receiving either drug-eluting or bare metal stents, provided that the patient is at low to intermediate risk for hemorrhage. Meanwhile, patients at high risk for hemorrhage should receive a bare metal stent and only 4 weeks of triple therapy. A new outpatient bleeding risk index developed for patients undergoing coronary stenting who need long-term oral anticoagulation seems to be useful for identifying patients at high risk of bleeding (79) .
Such a bleeding risk index might also be useful to identify patients post-ACS most likely to benefit from novel oral anticoagulant agents (e.g., factor IIa or Xa inhibitors) who are receiving dual antiplatelet therapy. This was highlighted by the premature termination of the APPRAISE-2 trial (80), which studied the combination of triple therapy post-ACS and suggests that such therapy may not be safe in older patients and in other patients at increased risk for bleeding. The results of the ATLAS-ACS 2 TIMI 51 trial evaluating the addition of the oral anti-Xa agent rivaroxaban to antiplatelet therapy in 15,526 patients will be available in late 2011 (81) .
Invasive Management
Key papers in the area of invasive management focused on the timing of coronary angiography, a comparison of outcomes between different stents, and 2 large studies in patients with left main disease who were randomized to PCI versus CABG.
A meta-analysis of 4 trials with 4,013 patients with NSTE-ACS compared an early-invasive (time to angiography ranging from 1.2 to 14 hours) with a delayed-invasive (angiography in 21 to 86 h) strategy (82) . There were no differences in death or in MI rates, but the early-invasive approach was associated with a 41% reduction in the risk of recurrent ischemia (p ϭ 0.02), a 28% reduction in the duration of hospital stay (p Ͻ 0.001), trends toward fewer bleeds (relative risk [RR]: 0.78; p ϭ 0.13), and major adverse cardiovascular events (death, MI, or stroke RR: 0.91; p ϭ 0.09).
A propensity-matched analysis of 4,776 pairs of patients with NSTEMI from the New York State PCI registry compared outcomes for patients receiving drug-eluting stents versus bare metal stents over a median follow-up of 3.7 years (83). Mortality differences in favor of drug-eluting stents were seen beginning at 6 months (2.9% vs. 4.3%; p Ͻ 0.001) and continuing through 4 years (14.5% vs. 16.6%; p Ͻ 0.001). In addition, patients receiving drug-eluting stents required less frequent need for repeat target vessel revascularization (11.0% vs. 13.1%; p ϭ 0.009). However, in a randomized trial of 2,314 patients with large (Ͼ3 mm) coronary arteries, one third of whom had unstable angina, there were no statistical differences in death or MI rates between either sirolimus-or everolimus-eluting stents and bare-metal stents (84) . However, when compared with the use of bare-metal stents, target vessel revascularization was reduced by more than one-half with use of either drugeluting stent, with no differences between sirolimus and everolimus. Similarly, 2 randomized trials comparing 2 new drug-eluting stents (zotarolimus vs. everolimus) in patients, two-thirds of whom had ACS, showed no differences in stent-related or clinical outcomes (85, 86) . Since the initial unstable angina guideline published in 1994 (87) , left main coronary artery stenosis 50% or higher was considered to be an indication for CABG. However, with the introduction of better interventional devices and improvements in adjunctive therapies during PCI, the question of whether PCI might be a reasonable alternative has been raised.
A randomized trial in patients, one-half of whom had ACS, with unprotected left main coronary artery stenosis, demonstrated that sirolimus-stenting was noninferior to CABG with respect to the primary composite of cardiac or cerebrovascular events at 1 year (88). However, this trial is difficult to interpret because the event rate was only twothirds of that anticipated and the noninferiority bounds were wide. Furthermore, as was seen in the subanalysis from the SYNTAX trial (89) and a second small randomized trial (90) , PCI is associated with greater need for subsequent revascularization than CABG in patients with left main coronary artery disease, especially among those at highest risk as defined by a SYNTAX score Ն33 (89). Furthermore, in these patients, CABG is more effective in relieving angina (91) . The current NSTE-ACS guideline (3) recommends CABG (Class IA) for patients with significant left main stenosis, and reserves PCI for patients not eligible for CABG or in whom emergent revascularization is needed due to hemodynamic instability (Class IIa-B).
Lipid-Lowering Therapies
New data on lipid-lowering therapies in patients with NSTE-ACS in the past year included research on the current use of statins and exploration of newer, more potent treatments. Data from hospitals participating in the CRUSADE and ACTION registries demonstrated several opportunities for improvement in lipid management (92) . Of patients admitted with ACS with a low-density lipoprotein level Ͼ100 mg/dl, only 37% had their statin dose uptitrated, as recommended by current guidelines (3). Furthermore, although 89% were receiving lipid-lowering therapy at discharge, 70% of patients did not achieve the more stringent goal of 70 mg/dl for patients post-ACS. A major barrier seems to be the underutilization of intensive lipid-lowering regimens that achieve Ͼ50% reduction in low-density lipoprotein (i.e., atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg, combinations of ezetimibe and statin). In the GWTG-CAD registry, only 38% of the 25,036 patients admitted with ACS were receiving an intensive lipid-lowering regimen at discharge (93) .
High-dose statins are limited by hepatic and muscle toxicity (94) and induce adverse effects on plasma cholesteryl-ester-transfer protein mass (95) . Thus, therapies that target other lipid particles, such as raising high-density lipoprotein with a cholesteryl-ester-transfer protein inhibitor (96) or niacin (97) , are being studied in Phase III clinical trials. In patients with ACS, Waksman et al. (98) demonstrated the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions. Favorable trends toward regression in atheromatous plaques were seen, although large-scale clinical trials evaluating the impact on clinical events are needed before these therapies would be widely accepted.
Quality
To date, research assessing the quality of care in NSTE-ACS has focused on acute management, such as early administration of antithrombotic therapy, beta-blockers, and coronary angiography in high-risk patients. However, the late consequences of ACS are frequently underappreciated and hence more attention to post-discharge therapy is warranted. In an analysis from the GRACE UK-Belgian Study, 5-year morbidity and mortality rates in patients after NSTE-ACS were as high as in patients with STEMI (99) . Optimal therapy post-NSTE-ACS was delivered to only 23% of patients in a Canadian registry (100) . This low rate of guideline-recommended therapy was most commonly attributed to the treating physician's belief that the patient lacked high-risk features and/or that there was no evidence to support the use of the guideline-recommended therapy in that clinical situation-reasons that were not supported by retrospective review of the data. Greater awareness of the evidence base, guideline recommendations, and coordination between caregivers (e.g., regarding the administration of influenza vaccines post-ACS [101] ) are required to further improve patient care.
